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Abstract
Purpose
To evaluate B-mode ultrasound as a novel method for objective and quantitative
assessment of a relative afferent pupillary defect (RAPD) in a prospective case-control
study.
Methods
Seventeen patients with unilateral optic neuropathy and a clinically detectable RAPD and 17
age and sex matched healthy controls were examined with B-mode ultrasound using an
Esaote-Mylab25 system according to current guidelines for orbital insonation. The swinging
flashlight test was performed during ultrasound assessment with a standardized light stimu-
lus using a penlight.
Results
B-mode ultrasound RAPD examination was doable in approximately 5 minutes only
and was well tolerated by all participants. Compared to the unaffected contralateral eyes,
eyes with RAPD showed lower absolute constriction amplitude of the pupillary diameter
(mean [SD] 0.8 [0.4] vs. 2.1 [0.4] mm; p = 0.009) and a longer pupillary constriction time
after ipsilateral light stimulus (mean [SD] 1240 [180] vs. 710 [200] ms; p = 0.008). In eyes
affected by RAPD, visual acuity correlated with the absolute constriction amplitude (r = 0.75,
p = 0.001).
PLOS ONE | https://doi.org/10.1371/journal.pone.0202774 August 27, 2018 1 / 9
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Schmidt FA, Connolly F, Maas MB,
Grittner U, Harms L, Brandt A, et al. (2018)
Objective assessment of a relative afferent pupillary
defect by B-mode ultrasound. PLoS ONE 13(8):
e0202774. https://doi.org/10.1371/journal.
pone.0202774
Editor: Raja Narayanan, LV Prasad Eye Institute,
INDIA
Received: May 16, 2018
Accepted: August 8, 2018
Published: August 27, 2018
Copyright: © 2018 Schmidt et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: F Schmidt has received
speaker honoraria from Genzyme, outside the
submitted work. K Ruprecht has received research
support from Novartis and Bundesministerium fu¨r
Bildung und Forschung (Competence Network
Multiple Sclerosis) as well as speaking fees or
Conclusions
B-mode ultrasound enables fast, easy and objective quantification of a RAPD and can thus
be applied in clinical practice to document a RAPD.
Introduction
A relative afferent pupillary defect (RAPD) is an impairment of the pupillary light reflex (PLR)
upon an ipsilateral light stimulus, typically due to ipsilateral optic nerve dysfunction [1]. At the
bedside, presence of a RAPD is commonly tested by the swinging flashlight test, during which a
penlight is swung from the unaffected eye to the affected eye while the PLR is observed. In path-
ological conditions, the pupil of the affected eye constricts normally following a contralateral
(indirect) light stimulus (Lstim), but shows a reduced or absent constriction, or even a paradoxi-
cal dilatation, following an ipsilateral (direct) Lstim [2]. The most common underlying pathology
of RAPD is optic neuritis (ON), which can occur in a variety of neuroimmunological disorders
such as multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte gly-
coprotein antibody associated encephalomyelitis or sarcoidosis [3–7]. While, in our center, B-
mode ultrasound is an established method for quantitatively measuring pupil diameter [8], the
role of B-mode ultrasound in the assessment of a RAPD has not been systematically studied so
far. Here, we evaluate B-mode ultrasound for objective and quantitative assessment of a RAPD.
Material and methods
Study participants
In this prospective case-control study, study participants were recruited from the Department
of Neurology and from the NeuroCure Clinical Research Center, Charite´–Universita¨tsmedizin
Berlin. Inclusion criteria were age 18 to 65 years, and a clinically detectable RAPD due to uni-
lateral ON. RAPD was diagnosed clinically by bedside examination with the swinging flash-
light test by a trained physician [2]. We excluded patients with a history of any ocular disease
other than ON (e.g. glaucoma, cataract, macular degeneration or diabetic retinopathy), those
who had undergone any type of ocular surgery in the past including laser surgery, and those
taking any topical or systemic medications known to potentially affect pupillary function. Data
from healthy controls were taken from a previous study on B mode ultrasound assessment of
the PLR in healthy individuals [8]. Healthy controls had no prior or current ophthalmologic
disease, no medications known to potentially affect pupillary function, and were selected from
our database to match patients for age (± 1 years) and sex.
Visual acuity testing
Habitual corrected visual acuity was determined under standardized light conditions using a
Snellen Chart with a distance of 2.8 meter [9].
B-mode ultrasound technique
All participants were studied in supine position under standardized dimmed light conditions
(room lighting 30 Lux). To adapt to the light level, study participants spent at least 10 minutes
in the ultrasound examination room before testing. All insonations were performed by the
same investigator (SJS) with the subject’s eyes closed using an Esaote Mylab 25 system (Esaote,
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Indianapolis, USA) equipped with a linear 10 MHz probe. Power settings were reduced to
minimum, according to the ALARA (as low as reasonably achievable) insonation approach
and current guidelines for orbital insonation [10]. B-mode settings were adjusted for near-
field eye examination. Each patient was examined lying flatly on the examination bed facing
towards the ceiling. Each pupil was visualized with the probe gently positioned at an angle of
20–30 degree from the examination bed on the lower eyelid of the closed eye, leveraging Bell’s
phenomenon [8]. For assessment of the PLR, patients had their eyes closed, a penlight was acti-
vated approximately 2 cm in front of each closed eye and the light reaction of each pupil was
digitally documented. In every examination the same standard penlight was used with a lumi-
nous emittance of 70,000 Lux and a stimulus time of 2 seconds to ensure constant wavelength,
intensity and duration of the light stimulus. Each assessment was performed in exactly the
same order, starting by measuring the pupillary diameter (PD) of the left eye at rest as well as
during ipsilateral and contralateral Lstim, followed by the same examinations of the right eye.
Data analyses
RAPDs were documented by recording video sequences of ultrasound examinations of the
PLR during performance of the swinging flashlight test [2]. PDs were manually assessed in a
frozen still image of the pupil, which was then digitally stored. Using the measuring tool of the
native application ultrasound system software, the largest diameter at rest and the smallest
diameter after Lstim were measured. Pupillary constriction time (PCT, measured in millisec-
onds) was defined as the time interval between the maximum and the minimum PD during
Lstim. PCT was manually determined using the AVSVideoConverter9.2 freeware (Online
Media Technologies Ltd. London, UK) in recorded 5 second video sequences of a second ipsi-
and contralateral Lstim, approximately 2 min after the PD analysis.
Statistical analyses
Statistical analyses were performed using SPSS 23.0 (IBM SPSS Statistics, New York, USA).
Graphs were created with GraphPadPrism 7.0 (GraphPad Software Inc, La Jola, USA). PD and
PCT are reported as mean ± standard deviation. PLR assessment measures in patients with
RAPD were compared with same-sided eyes of healthy controls using Student´s t-test for inde-
pendent samples for continuous variables or Mann-Whitney-U-test, depending on the distri-
bution. Differences between affected and non-affected eyes in patients were tested using
Wilcoxon signed-rank-test. Associations between visual acuity and PLR assessment measures
were analyzed using Pearson’s correlation coefficient. We also calculated the ratio of the con-
sensual/direct absolute constriction amplitude for each eye to quantitatively express the sever-
ity of the RAPD (“constriction ratio”). Correlation of the constriction ratio with visual acuity
was analyzed using Spearman’s rank correlation coefficient. P-values were corrected for multi-
ple testing according to the Bonferroni method [11]. Thus, each p-value was multiplied by the
number of statistical tests performed (n = 30). A two-sided significance level of α = 0.05 was
considered significant.
The study was approved by the institutional review board of Charite´—Universita¨tsmedizin
Berlin (EA1/190/15) and all participants provided written informed consent.
Results
Study participants
We studied 17 patients with unilateral ON and a clinically detectable RAPD. Of these, 5 had
ON as a clinically isolated syndrome (CIS), 4 had relapsing remitting multiple sclerosis
RAPD assessment by B-mode ultrasound
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according to the McDonald 2010 criteria [12], 6 had neuromyelitis optica spectrum disorder
according to the Wingerchuk 2015 criteria [13], and 2 had ON of unknown etiology. The
demographics and clinical characteristics of the patients and controls are summarized in
Table 1.
In patients with a RAPD, the visual acuity of affected eyes was significantly lower compared
to the same-sided eyes of controls (mean [SD] 0.4 [0.2] vs. 1.0 [0.1]; p<0.001) and compared
to the unaffected fellow eyes (0.4 [0.2] vs. 0.9 [0.1]; p = 0.008) (Table 2).
B-mode ultrasound for assessment of RAPD
The average ultrasound examination was doable in approximately five minutes and was well
tolerated by all participants. In all 17 patients with a clinically detectable RAPD, RAPD was
also detectable with B-mode ultrasound. Results of visual acuity testing, pupil diameter and
PCT assessment are summarized in Table 2. For illustration of RAPD assessment with B-mode
ultrasound, a video sequence of a 42-year-old male with left ON due to multiple sclerosis is
provided as supplementary video material (S1 Video).
Absolute constriction amplitudes
During ipsilateral Lstim of the affected eye the direct constriction amplitude was smaller in the
affected eyes compared to the same-sided eyes of controls (mean [SD] 0.8 [0.4] vs. 2.0 [0.5]
mm; p<0.001) and compared to the unaffected fellow eyes (0.8 [0.4] vs. 2.1 [0.4] mm;
p = 0.009) (Table 2). Consequently, during ipsilateral Lstim of the affected eye the consensual
constriction amplitude in the unaffected eye was smaller compared to same-sided eyes of con-
trols (mean [SD] 1.1 [0.5] vs. 1.9 [0.4] mm; p<0.001) and compared to the consensual con-
striction amplitude of affected eyes (1.1 [0.5] vs. 1.9 [0.5]; p = 0.019) (Table 2).
Constriction ratio
As a quantitative measure of RAPD severity we calculated the constriction ratio, defined as the
quotient of the consensual to direct constriction amplitudes. The constriction ratio was higher
in the affected eyes than in the same-sided eyes of controls (mean [SD] 2.8 [1.7] vs 1.0 [0.1];
p<0.001) and lower in the unaffected fellow eyes compared to controls (0.6 [0.2] vs. 1.0 [0.1];
p<0.001) (Table 2). To establish a cut-off value that distinguishes between pathological and
normal ratios, we calculated the mean + 3 standard deviations of the constriction ratio of the
control eyes (i.e. 1.3) and defined values above this value as pathological. As shown in Fig 1, a
threshold value of>1.3 discriminated eyes with a clinically-defined RAPD and healthy control
eyes without any overlap, suggesting that this measure could be used in clinical practice for a
diagnosis of a RAPD by B-mode ultrasound.
Table 1. Demographics and clinical characteristics.
Patients with ON (n = 17) Healthy Controls (n = 17)
Age (years)
mean (standard deviation) 43 (13) 43 (13)
Sex
Female/male 12/5 12/5
Time since ON onset (days)
median (minimum—maximum) 50 (5–5475) n.a.
ON = optic neuropathy, n.a. = not applicable
https://doi.org/10.1371/journal.pone.0202774.t001
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Pupillary constriction times
During ipsilateral Lstim, PCT was longer in the affected eyes compared to the same-sided eyes
of controls (mean [SD] 1240 [180] vs. 830 [130] ms; p<0.001) and compared to the unaffected
fellow eyes (1240 [180] vs. 710 [200] ms; p = 0.008). During contralateral Lstim, PCT was longer
in the unaffected eyes compared to the same-sided control eyes (mean [SD] 1080 [250] vs. 890
[100] ms; p<0.001) and compared to affected eyes (1080 [250] vs. 750 [190] ms; p = 0.007).
Correlation of visual acuity with pupillary constriction
The visual acuity of the affected eyes was correlated with the direct constriction amplitude of
the affected eye (r = 0.75, p = 0.001, Fig 2) and with the consensual constriction amplitude of
the contralateral eye (r = 0.74, p = 0.001). The visual acuity of the affected eye was inversely
correlated with the constriction ratio of the affected eye (r = -0.66, p = 0.004).
Discussion
We here report on the application of B-mode ultrasound as a novel method for the detection
and quantification of a RAPD. B-mode ultrasound assessment of RAPD was fast, simple and
well–tolerated, and enabled unambiguous detection of a RAPD in patients with a clinically
detectable RAPD due to unilateral ON. As expected, ultrasound measurements showed
Table 2. Visual acuity testing and ultrasound assessment.
Affected
eye
(n = 17)
Unaffected
eye
(n = 17)
HC
same-sided as affected
eye (n = 17)
HC
same-sided as unaffected
eye (n = 17)
p-valuea
(Affected eye vs.
HC)
p-valuea
(Unaffected eye vs.
HC)
p-valuea
(Affected vs.
Unaffected eye)
Visual Acuity
Decimal 0.4 (0.2) 0.9 (0.1) 1.0 (0.1) 1 (0.1) <0.001 > 0.999 0.008
PD at rest
(mm) 4.8 (0.7) 5.1 (0.6) 4.7 (0.9) 4.6 (0.9) > 0.999 > 0.999 0.390
PD during ipsilateral light stimulus
(mm) 4.0 (0.7) 3.0 (0.4) 2.6 (0.6) 2.8 (0.7) <0.001 > 0.999 0.008
Difference between PD at rest and during ipsilateral light stimulus (direct constriction amplitude)
(mm) 0.8 (0.4) 2.1 (0.4) 2.0 (0.5) 1.9 (0.3) <0.001 > 0.999 0.009
PD during contralateral light stimulus
(mm) 3.0 (0.6) 4.0 (0.7) 2.5 (0.6) 2.7 (0.6) 0.720 <0.001 0.009
Difference between PD at rest and during contralateral light stimulus (consensual constriction amplitude)
(mm) 1.9 (0.5) 1.1 (0.5) 2.0 (0.5) 1.9 (0.4) > 0.999 <0.001 0.019
Pupillary constriction time after ipsilateral light stimulus
(ms) 1240 (180) 710 (200) 830 (130) 880 (183) <0.001 0.800 0.008
Pupillary constriction time after contralateral light stimulus
(ms) 750 (190) 1080 (250) 850 (120) 890 (100) > 0.999 <0.001 0.007
RAPD assessment
Pos./
Neg.
17/0 0/17 0/17 0/17 - - - - - -
Constriction ratio of consensual to direct constriction amplitudes
2.8 (1.7) 0.6 (0.2) 1.0 (0.1) 1.0 (0.1) <0.001 <0.001 0.009
Values are given as mean ± standard deviation. HC = healthy controls, n = number, neg. = negative, pos. = positive, PD = pupillary diameter, RAPD = relative afferent
pupillary defect.
aBonferroni-corrected p-values according to the number of tests (n = 30).
https://doi.org/10.1371/journal.pone.0202774.t002
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reduced constriction amplitudes in both eyes following light stimulation of the affected eye
compared to contralateral light stimulation. Furthermore, the severity of the RAPD as assessed
by B-mode ultrasound correlated with the severity of visual acuity impairment.
Compared to standard clinical RAPD examination by the swinging flashlight test [1, 2],
advantages of RAPD testing by B-mode ultrasound include objective quantification of the
severity of a RAPD and digital documentation of results of RAPD examinations. Parameters
and ultrasound images can thus be stored and analyzed longitudinally in follow-up measure-
ments. Furthermore, the dynamic component of the PLR, the PCT, can be measured and doc-
umented as well.
The results for constriction amplitude differences obtained by B-mode ultrasound were
overall similar to those of studies examining patients with RAPD and controls with infrared
video pupillometry (IVP) [14–17]. While IVP allows for a marginally more detailed analysis of
the PLR [18], IVP devices are sophisticated tools with limited availability due to high acquisi-
tions costs. In contrast, ultrasound is a widely available standard diagnostic tool in most hospi-
tals and medical practices. Furthermore, unlike IVP, PLR assessment by ultrasound can be
performed with the patient´s eyes closed, so examinations are still feasible in cases in which
eyelid retraction is impeded.
To distinguish in clinical routine between healthy and pathological reactions, we propose a
threshold value of>1.3 of the consensual to direct constriction amplitude ratio as suggestive
Fig 1. Comparison of constriction ratio of consensual to direct constriction amplitude between affected and HC eyes. X-axis:
affected eyes and HC eyes. Y-axis: Constriction ratio of consensual to direct constriction amplitudes; the whiskers indicate minimum
and maximum values. HC = healthy controls, ON = optic neuritis.
https://doi.org/10.1371/journal.pone.0202774.g001
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of RAPD. To determine this threshold, we applied the “mean + 3 standard deviation of nega-
tive controls” formula, a widely used formula to determine cut-offs for biological tests [19].
The constriction ratio can be measured with B-mode ultrasound within approximately 2 min
and could help to identify a RAPD when it is not clearly detectable with the swinging flashlight
test [2]. Furthermore, constriction ratios could be longitudinally evaluated in follow-up exami-
nations to document RAPD severity and to monitor treatment effects in patients with inflam-
matory optic neuropathies. Determination of an RAPD by B-mode ultrasound can measure
functional integrity of the anterior visual pathway, whereas optical coherence tomography
measures structural damage of the retina, and visual evoked potentials measure functional
integrity of the entire visual pathway. B-mode ultrasound of the eye could thus complement
visual evoked potentials [6,20] and optical coherence tomography [21–24], in the assessment
of the visual pathway and could thus help to investigate afferent anterior visual pathway dam-
age in patients with inflammatory conditions, such as CIS, MS, NMOSD or MOG antibody
associated encephalomyelitis [25–29].
Of note, our findings may also have implications for treatment trials with visual endpoints.
For instance, one of the recent NMOSD trials investigating the clinical efficiency of a CD19
monoclonal antibody has implemented RAPD as an attack criterion [30]. Similar trials could
potentially benefit from a reliable and reproducible RAPD evaluation method such as the B-
mode ultrasound proposed here. Thus, longitudinal studies with follow-up measurements of
RAPD by ultrasound and their correlation to visual acuity and treatment response would be of
interest. Furthermore, it will be interesting to evaluate in patients with ON and no clinical sign
of RAPD whether subclinical RAPD can be detected by ultrasound.
Fig 2. Correlation of visual acuity with absolute constriction amplitude. X-axis: ACAdir = difference between pupillary diameter
at rest and during ipsilateral light stimulus, ON = optic neuritis. Y-axis: VA = visual acuity.
https://doi.org/10.1371/journal.pone.0202774.g002
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Altogether, B-mode ultrasound enables fast, easy and objective quantification of a RAPD
and can thus be applied in clinical practice to document a RAPD.
Supporting information
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